바이오공정 기술 시장 - 세계 시장 예측(2026-2032년)

The Bioprocess Technology Market is projected to grow by USD 105.23 billion at a CAGR of 12.59% by 2032.

Bioprocess Technology Executive Summary

Bioprocess technology is becoming a strategic backbone of modern biomanufacturing, enabling the controlled production of biologics, vaccines, cell and gene therapies, enzymes, biosimilars, recombinant proteins, and advanced therapeutic modalities. The field spans upstream processing, downstream purification, cell culture, microbial fermentation, process analytical technology, single-use systems, automation, and quality-by-design practices. Demand is being shaped by the rising global burden of chronic and infectious diseases, wider use of biologic therapies, expanding biosimilar development, and the need for faster, more resilient manufacturing networks. Regulatory expectations around product quality, traceability, sterility assurance, and process validation are also intensifying the adoption of closed processing, continuous biomanufacturing, digital monitoring, and robust contamination control strategies. As life sciences organizations pursue greater productivity, flexibility, and sustainability, bioprocess technology is shifting from a specialized production function to a core enabler of therapeutic innovation, supply security, and healthcare preparedness.

Transformative Shifts in the Bioprocess Technology Landscape

The bioprocess technology landscape is undergoing a fundamental shift from stainless-steel, batch-centric production toward flexible, modular, digitally enabled, and increasingly continuous manufacturing models. Single-use bioprocessing has gained traction because it can reduce cleaning requirements, shorten changeover times, support multiproduct facilities, and lower cross-contamination risk when implemented with appropriate validation and supply-chain controls. Intensified upstream processes, high-cell-density cultures, perfusion systems, and improved media formulations are helping manufacturers improve productivity while reducing facility footprints. In downstream processing, chromatography innovation, membrane-based separations, viral clearance technologies, and automation are addressing persistent bottlenecks caused by higher upstream titers. At the same time, cell and gene therapies are pushing the sector toward smaller, patient-specific, and decentralized production models that require closed systems, rapid release testing, and highly controlled logistics. Sustainability is also reshaping procurement and facility design as manufacturers evaluate water use, energy consumption, solvent reduction, plastic waste management, and lifecycle performance across bioprocess operations.

Cumulative Impact of Artificial Intelligence on Bioprocess Technology

Artificial intelligence is increasingly influencing bioprocess technology by improving process development, monitoring, scale-up, deviation management, and decision-making. AI-enabled models can analyze high-dimensional bioprocess data from bioreactors, sensors, chromatography systems, laboratory information systems, and manufacturing execution platforms to identify relationships that are difficult to detect through conventional statistical methods. In upstream processing, machine learning supports media optimization, feeding strategy design, cell growth prediction, and early detection of process drift. In downstream operations, AI can help optimize purification parameters, predict column performance, improve yield consistency, and support real-time quality assessment. Digital twins and hybrid modeling are gaining importance because they combine mechanistic bioprocess knowledge with data-driven learning, allowing teams to simulate process behavior before implementing changes on the manufacturing floor. However, the cumulative impact of AI depends on data integrity, validated models, explainability, cybersecurity, and alignment with good manufacturing practice requirements. Organizations that establish strong data governance, interoperable systems, and cross-functional collaboration between bioprocess scientists, automation engineers, quality teams, and regulatory specialists are better positioned to capture measurable operational value from AI.

Key Regional Insights for Bioprocess Technology

Asia-Pacific is strengthening its role in bioprocess technology through expanding biopharmaceutical manufacturing capacity, government support for biotechnology, growing biosimilar activity, and rising demand for vaccines and advanced therapies. China, India, Japan, South Korea, Australia, and Southeast Asian economies are investing in biomanufacturing infrastructure, workforce development, and regulatory modernization, while regional contract manufacturing capabilities continue to mature. Europe is characterized by strong regulatory oversight, biosimilar expertise, advanced biomanufacturing research, and sustainability-focused production practices, supported by established quality frameworks for biologics, vaccines, and cell therapy manufacturing. North America remains a major center for biologics innovation, advanced therapy development, clinical-scale biomanufacturing, and adoption of automation, single-use platforms, and process analytical technology, supported by strong research ecosystems and established regulatory frameworks. Latin America is advancing bioprocess capabilities through vaccine production initiatives, biologics access programs, and local manufacturing partnerships, with Brazil and Mexico playing important roles in regional healthcare supply resilience. Africa is building bioprocess relevance through public health manufacturing initiatives, vaccine localization efforts, regional regulatory strengthening, and partnerships intended to reduce dependency on imported biologics and improve access to essential therapies. The Middle East is developing life sciences manufacturing as part of broader healthcare diversification strategies, with increasing attention to local vaccine capacity, biologics supply security, sterile manufacturing, and technology transfer.

Key Group Insights for Bioprocess Technology

NATO countries, while not a commercial market grouping, have relevance to bioprocess technology through biosecurity, medical preparedness, resilient supply chains, and strategic manufacturing capacity for vaccines, antidotes, diagnostics, and critical biologics used in public health emergencies. The G7 remains highly influential in bioprocess innovation, quality regulation, funding for biomedical research, pandemic preparedness, and advanced manufacturing adoption, with member countries shaping standards for biologics, vaccines, and emerging therapeutic platforms. BRICS economies are important because they combine large patient populations, expanding domestic pharmaceutical industries, and policy interest in local biomanufacturing, although infrastructure maturity, regulatory capacity, and technology access vary across members. The European Union continues to influence the bioprocess technology sector through harmonized regulatory standards, strong biologics and biosimilar expertise, sustainability policies, and support for advanced therapy manufacturing across its member states. ASEAN is emerging as a practical growth corridor for bioprocess technology due to improving healthcare infrastructure, rising pharmaceutical investment, and regional interest in vaccine and biologics manufacturing, with member economies seeking stronger technology transfer and quality systems. The GCC is emphasizing healthcare self-sufficiency and biotechnology as part of national diversification agendas, creating opportunities for bioprocess facilities, fill-finish operations, biologics logistics, and regional manufacturing partnerships.

Key Country Insights for Bioprocess Technology

China is rapidly expanding biomanufacturing capacity, biosimilar development, vaccine capabilities, and advanced therapy research, supported by domestic policy focus on biotechnology and improving regulatory alignment. The United States is a leading hub for bioprocess technology innovation, supported by extensive biologics research, advanced therapy pipelines, automation adoption, strong regulatory science capabilities, and mature clinical manufacturing infrastructure. Japan is recognized for high-quality biologics manufacturing, regenerative medicine regulation, advanced automation, and a strong emphasis on manufacturing consistency. India is a major contributor to vaccines, biosimilars, and cost-efficient biomanufacturing, with growing investment in process development, analytical capabilities, and quality systems. Germany combines engineering strength, biologics manufacturing expertise, strong process automation capabilities, and established biopharmaceutical production know-how. The United Kingdom remains influential in cell and gene therapy development, translational research, clinical trial infrastructure, and bioprocess skills development. Australia supports bioprocess technology through clinical research, biologics development, public health manufacturing initiatives, and regional supply resilience programs. France supports bioprocess technology through vaccine, biologics, and biomanufacturing initiatives, with attention to industrial modernization and health security. South Korea has become a prominent biomanufacturing center with strong biologics production capabilities, government-backed biotechnology programs, and increasing expertise in contract development and manufacturing. Italy and Spain contribute to European bioprocessing through pharmaceutical manufacturing, biosimilar activity, clinical research networks, and aseptic production capabilities. Canada is strengthening biomanufacturing through public health preparedness, vaccine capacity initiatives, and investment in life sciences infrastructure. Russia maintains activity in vaccine and biologics production with emphasis on domestic supply and biotechnology self-reliance. Brazil is central to Latin American bioprocess development due to its biologics demand, vaccine production history, public health manufacturing capabilities, and technology transfer experience. Mexico benefits from proximity to North American pharmaceutical supply chains and is gradually expanding its role in manufacturing, clinical supply, sterile operations, and healthcare access.

Actionable Recommendations for Bioprocess Technology Leaders

Industry leaders should prioritize flexible bioprocess architectures that combine single-use technologies, closed processing, modular facility design, and scalable automation to support faster product transitions and multiproduct operations. Strengthening digital maturity is essential, including investment in process analytical technology, real-time data capture, validated AI models, electronic batch records, and interoperable manufacturing systems. Organizations should address downstream bottlenecks early in process development by optimizing purification strategies, resin utilization, membrane performance, and viral clearance design. To improve resilience, leaders should diversify critical suppliers for single-use components, culture media, resins, filters, sensors, and sterile connectors while maintaining rigorous supplier qualification and change-control processes. Workforce development should focus on bioprocess engineering, data science, automation, aseptic operations, quality systems, and regulatory readiness. Sustainability should be embedded through lifecycle assessment, waste reduction, water and energy efficiency, and responsible materials management. For advanced therapies, leaders should design closed, traceable, and patient-centric manufacturing workflows that reduce manual intervention and support reliable chain-of-identity and chain-of-custody controls.

Research Methodology

This executive summary is developed using a structured secondary research approach centered on verified public-domain and industry-recognized sources, including regulatory guidance, scientific literature, public health agency materials, patent and standards references, clinical development trends, manufacturing technology publications, pharmacopeial standards, and government biotechnology initiatives. The analysis emphasizes triangulation across multiple credible sources to identify consistent patterns in bioprocess technology adoption, regional manufacturing development, artificial intelligence integration, regulatory expectations, and operational best practices. Qualitative assessment focuses on technology maturity, manufacturing use cases, policy direction, supply-chain considerations, and therapeutic application areas. The methodology deliberately excludes market sizing, market share calculations, financial forecasting, and speculative estimates, ensuring the summary remains focused on validated industry dynamics, evidence-based technology trends, and strategic implications for stakeholders.

Conclusion

Bioprocess technology is advancing rapidly as biologics, vaccines, biosimilars, and advanced therapies demand faster, cleaner, more flexible, and more data-driven manufacturing systems. The convergence of single-use platforms, continuous processing, process analytical technology, AI-enabled modeling, closed manufacturing, and sustainability-focused operations is redefining how therapeutic products are developed and produced. Regional and country-level initiatives are reinforcing the importance of local biomanufacturing capacity, quality infrastructure, regulatory readiness, and resilient supply chains. Organizations that combine scientific rigor with digital transformation, regulatory discipline, supplier resilience, and skilled talent development will be best positioned to improve productivity, accelerate technology transfer, and maintain consistent product quality in an increasingly complex biopharmaceutical environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Bioprocess Technology Market, by Process Mode

• 7.1. Introduction
• 7.2. Batch
• 7.3. Continuous
  • 7.3.1. Chemostat
  • 7.3.2. Perfusion
• 7.4. Fed Batch
  • 7.4.1. Exponential Fed
  • 7.4.2. Pulse Fed

8. Bioprocess Technology Market, by Material

• 8.1. Introduction
• 8.2. Hybrid
• 8.3. Single-Use
  • 8.3.1. Rocking Motion Bioreactor
  • 8.3.2. Stirred-Tank Single-Use
  • 8.3.3. Wave Bioreactor
• 8.4. Stainless Steel

9. Bioprocess Technology Market, by Scale

• 9.1. Introduction
• 9.2. Clinical Scale
• 9.3. Commercial Scale
• 9.4. Pilot Scale

10. Bioprocess Technology Market, by Application

• 10.1. Introduction
• 10.2. Cell Therapy And Regenerative Medicine
  • 10.2.1. CAR-T Therapy
  • 10.2.2. Stem Cell Therapy
• 10.3. Monoclonal Antibody Production
• 10.4. Recombinant Protein Production
• 10.5. Vaccine Production
  • 10.5.1. mRNA Vaccine
  • 10.5.2. Subunit Vaccine

11. Bioprocess Technology Market, by End User

• 11.1. Introduction
• 11.2. Academic And Research Institutes
• 11.3. Biopharmaceutical Companies
• 11.4. Contract Manufacturing Organizations

12. Bioprocess Technology Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Bioprocess Technology Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Bioprocess Technology Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. ABEC, Inc.
• 16.2. AdvantaPure
• 16.3. Agilent Technologies, Inc.
• 16.4. Avantor, Inc.
• 16.5. Bio-Rad Laboratories, Inc.
• 16.6. CellGenix GmbH
• 16.7. Colder Products Company
• 16.8. Corning Incorporated
• 16.9. Cytiva
• 16.10. Danaher Corporation
• 16.11. Eppendorf SE
• 16.12. GEA Group AG
• 16.13. Getinge AB
• 16.14. Hamilton Company
• 16.15. Lonza Group AG
• 16.16. Meissner Filtration Products, Inc.
• 16.17. Merck KGaA
• 16.18. PBS Biotech, Inc.
• 16.19. Repligen Corporation
• 16.20. SaniSure
• 16.21. Sartorius AG
• 16.22. Takara Bio Inc.
• 16.23. Thermo Fisher Scientific Inc.